From a discovery to innovation
Lymphoma research particularly aims to better understand this cancer and to improve its treatment. It has rapidly progressed over the last few years and has significantly evolved, based on stronger interactions between lymphoma specialists, especially within the Lymphoma Research Experts ecosystem.
The Lymphoma Research Specialists ecosystem gathers complementary expertise covering all research aspects, from basic research and non-clinical research to clinical research.
- Basic and non-clinical research: improving knowledge about lymphomas and making major discoveries about this cancer
- Translational research: ensures the bidirectional transfer of information between basic and non-clinical research on the one hand, and clinical research on the other.
- Clinical research: essential evaluation of research avenues in studies on humans
Basic and non-clinical research
Basic and non-clinical research is a crucial phase in lymphoma research. It is a precious source of new knowledge that can open a path to the development of concrete applications for the benefit of the patients.
Within the Lymphoma Research Experts ecosystem, several academic teams joined together in the Carnot Institute CALYM conduct basic and non-clinical research projects. Their fields of expertise are varied, and especially concern:
- Tumour development mechanisms
- Tumour microenvironment
- Diagnostic, prognostic, theranostic biomarkers
Translational research is the bridge between basic and non-clinical research and clinical research. It aims to facilitate the transfer of new scientific knowledge into medical and technical progress.
Accelerating translational research is one of the aims shared by the member organisations of the Lymphoma Research Experts ecosystem. Tight cooperation between the various lymphoma research experts is necessary to transform scientific discoveries into innovating and concrete applications for the benefit of the patients.
Clinical research includes all studies conducted on humans. It is particularly important for the large-scale use of new treatments or new care modalities.
Conducting clinical trials on new therapeutic solutions is a key activity within the Lymphoma Research Experts ecosystem. The LYSA Cooperating Group and its LYSARC operational structure possess the expertise and the means necessary to conduct clinical trials, from the first tests on humans to the registration studies of a new treatment.
- The so-called phase I or II trials aim to evaluate the effectiveness and toxicity of the new medicines, alone or in combination. They are important in order to determine whether a medicine has a chance to be truly useful or not, and to design so-called phase III clinical trials.
- The so-called phase III trials compare the benefit of the new medicine, associated with or replacing a classic or standard treatment. The trials are extremely important. For one thing, they define the most effective treatment strategies. For another, they make it possible for the health authorities to register new medicines, which can then be used in everyday practice to treat a disease.
At the end of the strategic trials mentioned above, the LYSA and LYSARC are also able to conduct complementary studies, that especially allow the long-term monitoring of patients to evaluate the stability of the initial therapeutic results and to identify potential late complications of the treatments under study.